Award Data

DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therapy for prostate cancer. The desired outcomes are improved local control rate, decreased recurrence and improved disease-free survival. This grant ...

DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to increase the throughput of our DNA sequencing instrument to enable whole genome sequencing with high efficiency and accuracy for a cost of under 1000 per genome. In Phase I, we developed a working sequencing assay, a microfluidic platform and camera system, and analysis methodology that enable genome alignment and variant ca ...

DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( smart pumps ). A proprietary approach is proposed basedon the favorable physico-chemical properties conferred by chloro-aromatic substitutions in the insulin molecule. This Phase 2 SBIR application th ...

DESCRIPTION (provided by applicant): we proposed to develop a novel drug, 4-CI-KYN to treat neuropathic pain. 4-CI-KYN is a pro-drug of 7-Chlorokynurenic acid (7-Cl-KYNA), a chlorinated analogue of kynurenic acid, which is a natural neuromodulator and one of the most potent and specific GlyB antagonists known to man, which blocks glutamate transmission through the NMDA receptor. This receptor is i ...

DESCRIPTION (provided by applicant): The aim of the proposed project is to develop an advanced, web-based knowledge management system for the creation and distribution of multilingual, patient-oriented documents. The system provides a vast library of pre-translated documents and document templates for medical, educational, and administrative materials used in patient-care. System users will be abl ...

This project is aimed at the development of an enzyme immunoassay (ELISA) for screening blood for antibodies to Babesia microti. Human babesiosis is a malaria-like illness due to infection of red blood cells by various species of protozoan parasites belonging to the genus Babesia. Most human infections reported in the United States are caused by B. microti which is endemic in parts of the northeas ...

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) and their collaborators have investigated additional tr ...

DESCRIPTION (provided by applicant): Peripheral artery disease and trauma are leading causes of morbidity and amputation in the United States. Recent advances in biomaterials provide for potential development of small diameter vascular grafts as a life-saving treatment. Development of a life-long graft (lt 6 mm id) requires a construct that will not cause significant blood clotting/thrombosis and ...

DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permit the delivery of genes, which express proteins that stimulate the immune system. An advanced generation of Ad vectors with unique deletions of ...

DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step in the recruitment of white blood cells to sites of inflammation. Vasoocclusion is precipitated by a P- selectin-mediated adhesion of sickled red ...